Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Multicenter Study of Itolizumab in Combination With Corticosteroids for the Initial Treatment of Acute Graft Versus Host Disease

NCT05263999 is registered in ClinicalTrials.gov with Equillium as lead sponsor.

NCT NCT05263999
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05263999 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Multicenter Study of Itolizumab in Combination With Corticosteroids for the Initial Treatment of Acute Graft Versus Host Disease
Lead sponsor
Equillium
Phase
Phase 3
Overall status
Terminated
Start date
April 29, 2022
Completion date
May 12, 2025
Enrollment
158 (actual)
Sites
118

Conditions

As the registry lists them; a condition with its own page is linked.

acute gvhd, acute-graft-versus-host disease, agvhd, graft versus host disease, gvhd